AliveCor Kardia 12L Receives CE Mark Approval
▼ Summary
– The Kardia 12L is a portable, AI-powered 12-lead ECG device that uses a five-electrode, single-cable design to replace bulky traditional ECG carts.
– It has received CE Mark approval, enabling its initial launch for healthcare professionals in France, Germany, Italy, Spain, and the UK.
– The device’s AI system, KAI 12L, can detect 35 cardiac conditions, including acute myocardial infarction and various arrhythmias.
– Its portable design is intended for use in primary care, pharmacies, and home visits where standard ECG equipment is impractical.
– The system has been used globally on tens of thousands of patients and has already identified thousands of instances of serious cardiac events.
A major advancement in portable cardiac diagnostics has arrived in Europe. AliveCor’s Kardia 12L ECG system has secured CE Mark approval, clearing the way for its introduction to healthcare professionals across the European Economic Area. This authorization represents a significant step in expanding access to advanced, AI-driven heart monitoring technology outside the United States.
The device is distinguished by its innovative design. It replaces cumbersome traditional 10-electrode ECG carts with a streamlined, five-electrode single-cable system that weighs a mere 130 grams. This portable 12-lead ECG is battery-powered and pocket-sized, making it ideally suited for use in primary care clinics, pharmacies, urgent care centers, and during home visits where larger, more complex equipment is not feasible. The simplified electrode setup also offers a practical benefit for patients, as it does not require full disrobing for a reading.
At the core of the system is its AI engine, known as KAI 12L. In this CE-marked iteration, the artificial intelligence is capable of detecting 35 distinct cardiac determinations. This comprehensive analysis includes 14 different arrhythmias and 21 morphological conditions, with critical diagnoses like acute myocardial infarction and common forms of cardiac ischaemia among them. The underlying algorithm was trained and validated on a massive dataset of over 1.75 million ECGs sourced from leading American medical institutions.
Clinical utility is already being demonstrated at scale. Since receiving FDA clearance and launching commercially in the U. S. in June 2024, the Kardia 12L has been deployed globally on tens of thousands of patients. AliveCor reports the system has successfully identified more than 4,000 instances of myocardial infarction and ischaemia to date. Furthermore, a peer-reviewed study highlighted a nearly 30% reduction in ECG acquisition time compared to standard setups, enhancing workflow efficiency for clinicians.
The initial European rollout will focus on France, Germany, Italy, Spain, and the United Kingdom, with plans to expand to additional countries. This launch aligns with broader European health initiatives, such as the EU Cardiovascular Health Plan, which emphasizes early detection and improved care access for cardiovascular diseases, the continent’s leading cause of death.
Company executives frame the CE Mark as a pivotal achievement. Simona Esposito, AliveCor’s Senior Vice President of Sales for Global Markets, called it a defining moment for their international strategy, underscoring that the device was engineered specifically for clinical environments where traditional ECG carts are impractical. AliveCor, a privately-held firm based in California, has now recorded more than 350 million ECGs across its entire Kardia product portfolio, solidifying its position in the digital cardiology space.
(Source: The Next Web)
